#LiverCancer Archives

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

By El Bachir MOURABIT 2024.12.02

Hepatocellular carcinoma (HCC) imposes a significant health and economic burden on patients. Screening, recognized as an effective strategy to improve early diagnosis rates in high-risk populations, has garnered broad acknowledgment…

AASLD 2024丨Dr. Qing Xie ‘s Team: Digital Precision Screening and Risk Stratification Improve Early Detection of Liver Cancer in China

By Mourabit Halima 2024.11.29

Liver cancer poses a significant public health challenge in China, with approximately 367,700 new cases in 2022, accounting for 42.5% of global incidence. However, the five-year survival rate is a…

ILCA Chair Interview | Dr. Tim Meyer: Focusing on Advances in Liver Cancer Treatment and Shaping Future Progress

By Lisa Cui 2024.11.06

From October 17 to 19, 2024, in the season of golden autumn, the 18th International Liver Cancer Association (ILCA) Annual Conference was successfully held. This grand event attracted numerous top…

Advancing Liver Cancer Treatment: Insights from Professor Tim Meyer

By Peng Longmei 2024.10.23

In a recent discussion, Professor Tim Meyer highlighted the importance of multidisciplinary care in liver cancer treatment. As systemic therapies evolve, including combinations of tyrosine kinase inhibitors and immunotherapy, there’s…

2024 CACA丨 How to Balance Hepatic Adjuvant Therapy? Dr. Minshan Chen Shares Advances and Strategies in Liver Cancer Adjuvant Treatment

By Peng Longmei 2024.10.09

Hepatocellular carcinoma (HCC), often called the "king of cancers," not only has a low survival rate in advanced stages but also carries a high risk of postoperative recurrence, with a…

Dr. Feng Wang: Current Status and Challenges of Hepatocellular Carcinoma (HCC) Conversion Therapy in the Era of Integrated Medicine

By Lisa Cui 2024.10.08

Liver cancer is one of the most common malignant tumors in China, ranking second in cancer-related deaths. This highlights the significant burden of liver cancer prevention and treatment in the…

Dr Wai-Kay Seto’s Team: Optimized Glycemic Control Reduces Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Diabetes

By El Bachir MOURABIT 2024.09.29

Editor's Note: Liver cancer ranks as the third leading cause of cancer deaths globally, with a fatality rate as high as 85%. Diabetes mellitus (DM) emerges as a significant risk…

VITALITY Study Results Announced: Immunotherapy Shows Great Promise as a Neoadjuvant Treatment Before Liver Transplantation in Liver Cancer

By Lisa Cui 2024.09.19

Editor's Note: Immune checkpoint inhibitors (ICI) are gradually becoming a key therapeutic strategy in the neoadjuvant treatment of advanced hepatocellular carcinoma (HCC). Their widespread application reflects the deep understanding and…

JHEP | MASLD Without Cirrhosis Still Poses High Liver Cancer Risk, Presenting Challenges for Clinical Management

By El Bachir MOURABIT 2024.09.10

Editor's Note: Metabolic-associated steatotic liver disease (MASLD) has become the fastest-growing cause of hepatocellular carcinoma (HCC). A recent multicenter clinical study led by Dr. Carole Vitellius from Angers University Hospital,…

Expert Insight | Dr. Guangxin Li: Latest Clinical Research Progress on Radiotherapy Combined with Immunotherapy for Liver Cancer

By Mourabit Halima 2024.02.16

Editor's Note: In recent years, with the continuous improvement of radiotherapy technology, not only has the effectiveness of tumor reduction been optimized compared to the past, but it has also…